These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34731268)

  • 1. An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder.
    Haass-Koffler CL; Perciballi R; Magill M; Loche A; Cacciaglia R; Leggio L; Swift RM
    Psychopharmacology (Berl); 2022 Jan; 239(1):35-46. PubMed ID: 34731268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study.
    Farokhnia M; Schwandt ML; Lee MR; Bollinger JW; Farinelli LA; Amodio JP; Sewell L; Lionetti TA; Spero DE; Leggio L
    Transl Psychiatry; 2017 Apr; 7(4):e1108. PubMed ID: 28440812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline.
    Miranda R; O'Malley SS; Treloar Padovano H; Wu R; Falk DE; Ryan ML; Fertig JB; Chun TH; Muvvala SB; Litten RZ
    Alcohol Clin Exp Res; 2020 Jul; 44(7):1431-1443. PubMed ID: 32363592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial.
    Ray LA; Bujarski S; Shoptaw S; Roche DJ; Heinzerling K; Miotto K
    Neuropsychopharmacology; 2017 Aug; 42(9):1776-1788. PubMed ID: 28091532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mifepristone as a pharmacological intervention for stress-Induced alcohol craving: a translational crossover randomized trial.
    Haass-Koffler CL; Magill M; Cannella N; Brown JC; Aoun EG; Cioe PA; Sinha R; Swift RM; Ciccocioppo R; Leggio L
    medRxiv; 2023 Jan; ():. PubMed ID: 36711869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous administration of ghrelin increases serum cortisol and aldosterone concentrations in heavy-drinking alcohol-dependent individuals: Results from a double-blind, placebo-controlled human laboratory study.
    Haass-Koffler CL; Long VM; Farokhnia M; Magill M; Kenna GA; Swift RM; Leggio L
    Neuropharmacology; 2019 Nov; 158():107711. PubMed ID: 31310775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A human laboratory study of the effects of quetiapine on subjective intoxication and alcohol craving.
    Ray LA; Chin PF; Heydari A; Miotto K
    Psychopharmacology (Berl); 2011 Oct; 217(3):341-51. PubMed ID: 21487653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial.
    Burnette EM; Baskerville WA; Grodin EN; Ray LA
    Trials; 2020 Sep; 21(1):779. PubMed ID: 32912290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers.
    Haass-Koffler CL; Goodyear K; Long VM; Tran HH; Loche A; Cacciaglia R; Swift RM; Leggio L
    Eur J Pharm Sci; 2017 Nov; 109():78-85. PubMed ID: 28778464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study.
    Lee MR; Tapocik JD; Ghareeb M; Schwandt ML; Dias AA; Le AN; Cobbina E; Farinelli LA; Bouhlal S; Farokhnia M; Heilig M; Akhlaghi F; Leggio L
    Mol Psychiatry; 2020 Feb; 25(2):461-475. PubMed ID: 29728704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Oxytocin Administration on Cue-Induced Craving in Co-occurring Alcohol Use Disorder and PTSD: A Within-Participant Randomized Clinical Trial.
    Stauffer CS; Meinzer NK; Morrison T; Wen JH; Radanovich L; Leung D; Niles A; O'Donovan A; Batki SL; Woolley JD
    Alcohol Clin Exp Res; 2019 Dec; 43(12):2627-2636. PubMed ID: 31610033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation.
    Farokhnia M; Deschaine SL; Sadighi A; Farinelli LA; Lee MR; Akhlaghi F; Leggio L
    Mol Psychiatry; 2021 Feb; 26(2):545-555. PubMed ID: 30382188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nalmefene attenuates neural alcohol cue-reactivity in the ventral striatum and subjective alcohol craving in patients with alcohol use disorder.
    Karl D; Bumb JM; Bach P; Dinter C; Koopmann A; Hermann D; Mann K; Kiefer F; Vollstädt-Klein S
    Psychopharmacology (Berl); 2021 Aug; 238(8):2179-2189. PubMed ID: 33846866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pregnenolone effects on provoked alcohol craving, anxiety, HPA axis, and autonomic arousal in individuals with alcohol use disorder.
    Milivojevic V; Sullivan L; Tiber J; Fogelman N; Simpson C; Hermes G; Sinha R
    Psychopharmacology (Berl); 2023 Jan; 240(1):101-114. PubMed ID: 36445398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G-CuP: the effect of a forced oral glucose intake on alcohol craving and mesolimbic cue reactivity in alcohol dependence-study protocol of a randomized, double-blind, placebo-controlled crossover study.
    Wetzel L; Pourbaix M; Riegler A; Pfeifer AM; Reinhard I; Hoffmann S; Vollstädt-Klein S; Kiefer F; Sommer W; Bumb JM; Bach P; Koopmann A
    Trials; 2022 Aug; 23(1):693. PubMed ID: 35986409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baclofen for alcohol use disorder.
    Agabio R; Saulle R; Rösner S; Minozzi S
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012557. PubMed ID: 36637087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals.
    Logge WB; Morris RW; Baillie AJ; Haber PS; Morley KC
    Psychopharmacology (Berl); 2021 May; 238(5):1291-1302. PubMed ID: 30788529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baclofen for alcohol use disorder.
    Minozzi S; Saulle R; Rösner S
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012557. PubMed ID: 30484285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of varenicline on alcohol cue reactivity in heavy drinkers.
    Roberts W; Harrison ELR; McKee SA
    Psychopharmacology (Berl); 2017 Sep; 234(18):2737-2745. PubMed ID: 28600734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety.
    Falk DE; Ryan ML; Fertig JB; Devine EG; Cruz R; Brown ES; Burns H; Salloum IM; Newport DJ; Mendelson J; Galloway G; Kampman K; Brooks C; Green AI; Brunette MF; Rosenthal RN; Dunn KE; Strain EC; Ray L; Shoptaw S; Ait-Daoud Tiouririne N; Gunderson EW; Ransom J; Scott C; Leggio L; Caras S; Mason BJ; Litten RZ;
    Alcohol Clin Exp Res; 2019 Jan; 43(1):158-169. PubMed ID: 30403402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.